At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 86 enrolled
Drug / intervention
Placebo +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized, Double-blind, Multi-centre, Placebo-controlled, Parallel-arm Phase 2 Trial to Assess Safety, Efficacy and Pharmacokinetics of CD11301 0.03% and 0.06% Gel in the Treatment of Cutaneous T-Cell Lymphoma (CTCL), Stages IA, IB and IIA
In Brief
A Phase 2 clinical trial evaluating Placebo, CD11301 0.03%, and 1 other intervention for Cutaneous T Cell Lymphoma. Completed, enrolled 86 participants across 21 sites in 3 countries.
Detailed Summary
To assess the efficacy, safety and pharmacokinetics in participants treated with CD11301 gel vs. placebo for early stage CTCL (IA, IB, or IIA).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCutaneous T Cell Lymphoma
CountriesFrance, Germany, United States
Collaborators--
Timeline
Phase 2CompletedFinished
201820192020202120222023202420252026
First PostedSep 2017
Enrollment StartDec 2017
Primary CompletionMar 2020
TodayJul 2026
First PostedSep 25, 2017
Enrollment StartDec 19, 2017
Primary CompletionMar 17, 2020
TodayJul 2, 2026
Enrollment to primary: 2.2 yearsPosted 8.8 years ago
Interventions
Placebodrug
Non active ingredients of CD11301
CD11301 0.03%drug
Topical Gel
CD11301 0.06%drug
Topical Gel